Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models (Q42828243)

8 November 2017

title

Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models (English)

1 reference

8 November 2017

1 reference

Liu M

1

1 reference

8 November 2017

Bishop WR

2

1 reference

8 November 2017

Nielsen LL

3

1 reference

8 November 2017

Bryant MS

4

1 reference

8 November 2017

Kirschmeier P

5

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

8 November 2017

published in

Methods in Enzymology

1 reference

8 November 2017

volume

333

1 reference

8 November 2017

page(s)

306-318

1 reference

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

Expression cloning of a novel farnesylated protein, RDJ2, encoding a DnaJ protein homologue

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2801%2933065-3

7 January 2021

10.1016/S0076-6879(01)33065-3

Identifiers

DOI

1 reference

8 November 2017

1 reference